Denis J. Schrier - Concepedia

Author

Denis J. Schrier

Also Known As

D J Schrier, D Schrier, D. J. SCHRIER, D. J. Schrier, D. SCHRIER, D. Schrier, D.J Schrier, D.J. Schrier, Denis J Schrier, Denis J. Schrier

Publications

4.5K

Citations

H-Index

Concepts

All Affiliations

University of Michigan Pfizer (United States)Warde Medical Laboratory Medical College of Wisconsin Gaertner (United States)

About

Denis J. Schrier is an author at University of Michigan specializing in medicine, immunology, and pharmacology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	24	35	2.5K
2	Biochemistry	12	13	1.2K
3	Natural Sciences	11	12	1.1K
4	Allergy	7	7	235
5	Cell Biology	5	5	130

Denis J. Schrier

Publications

4.4K

Citations

H-Index

Page 1

	Year	Citations
Weight bearing as a measure of disease progression and efficacy of anti-inflammatory compounds in a model of monosodium iodoacetate-induced osteoarthritis Susan E. Bove, Salvatore Calcaterra, Rachel M. Brooker, Osteoarthritis and Cartilage InflammationWeight BearingRheumatoid DisorderAnti-inflammatoryMedicine	2003	497
Identification of inducible brown adipocyte progenitors residing in skeletal muscle and white fat Tim J. Schulz, Tian Lian Huang, Thien T. Tran, Proceedings of the National Academy of Sciences	2010	449
Design of 5-(3,5-di-tert-butyl-4-hydroxyphenyl)-1,3,4-thiadiazoles, -1,3,4-oxadiazoles, and -1,2,4-triazoles as orally active, nonulcerogenic antiinflammatory agents Michael D. Mullican, Michael W. Wilson, David T. Conner, Journal of Medicinal Chemistry Combinatorial ChemistryPharmaceutical ScienceLog POrganic ChemistryPharmacotherapy	1993	372
1,3,4-Oxadiazole, 1,3,4-thiadiazole, and 1,2,4-triazole analogs of the fenamates: in vitro inhibition of cyclooxygenase and 5-lipoxygenase activities Diane H. Boschelli, David T. Connor, Dirk A. Bornemeier, Journal of Medicinal Chemistry Compound 5BMedicinal ChemistryVitro InhibitionBiochemistryMedicine	1993	202
Novel 1,2,4-oxadiazoles and 1,2,4-thiadiazoles as dual 5-lipoxygenase and cyclooxygenase inhibitors Paul C. Unangst, G. P. SHRUM, D. T. CONNOR, Journal of Medicinal Chemistry	1992	192
The Role of Strain Variation in Murine Bleomycin-lnduced Pulmonary Fibrosis <sup>1,</sup> <sup>2</sup> Denis J. Schrier, Robin G. Kunkel, Sem H. Phan American Review of Respiratory Disease	1983	186
Synthesis and biological evaluation of 5-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]methylene]oxazoles, -thiazoles, and -imidazoles: novel dual 5-lipoxygenase and cyclooxygenase inhibitors with antiinflammatory activity Paul C. Unangst, David T. Connor, Wiaczeslaw A. Cetenko, Journal of Medicinal Chemistry	1994	162
The Effects of the Nude <i>(nu/nu)</i> Mutation on Bleomycin-induced Pulmonary Fibrosis Denis J. Schrier, Sem H. Phan, Bridget McGarry American Review of Respiratory Disease	1983	149
In vivo selective inhibition of mitogen‐activated protein kinase kinase 1/2 in rabbit experimental osteoarthritis is associated with a reduction in the development of structural changes Jean‐Pierre Pelletier, Julio Fernandes, Julie Brunet, Arthritis & Rheumatism	2003	135
Synthesis, Structure−Activity Relationships, and in Vivo Evaluations of Substituted Di-<i>tert</i>-butylphenols as a Novel Class of Potent, Selective, and Orally Active Cyclooxygenase-2 Inhibitors. 1. Thiazolone and Oxazolone Series Yuntao Song, David T. Connor, Robert Doubleday, Journal of Medicinal Chemistry Pharmaceutical ScienceChemoprevention StrategyPharmacotherapyPharmaceutical ChemistryDrug Resistance	1999	130

Page 1